Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

No intervention. Each patient will have blood drawn at a standard of care venipuncture.

Frederick Lansigan, MD

The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers

Demonstrate that CLL cells also possess the enzymatic machinery for fatty acid acquisition and synthesis as shown by the expression of LPL, CD36, SDC1, and fatty acid synthase

American Cancer Society, Inc.

Dartmouth-Hitchcock Medical Center

Assistant Professor of Medicine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia	NCT01460238	Chronic Lymphoc...		18 Years -	Dartmouth-Hitchcock Medical Center
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia	NCT01460238	Chronic Lymphoc...		18 Years -	Dartmouth-Hitchcock Medical Center

Spots Global Cancer Trial Database for lipoprotein lipase